Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Partnering 600x60px
Document › Details

Gyros AB. (3/25/14). "Press Release: EMD Millipore Launches New Kits for Use on Gyros’ Immunoassay Platform". Uppsala.

Organisations Organisation Gyros AB
  Today Gyros Protein Technologies AB
  Group Gyros (Group)
  Organisation 2 Merck Millipore Division (EMD Millipore Division)
  Group Merck (DE) (Group)
Products Product GyroMark™ HT kit
  Product 2 Gyrolab™ xP workstation
Index term Index term Gyros–Merck (DE): immunoassay kits, 201307– collab developm + manufacturing + commercialisation of kits for Gyrolab platform by EMD Millipore
Persons Person Mistry, Jehangir (Merck (DE) 201201 Director RnD at EMD Millipore)
  Person 2 Hjortsmark, Maria (Gyros 201307 Global Marketing Director before Halo Genomics CBO)
     


> Simple, automated, nanoliter-scale assays requiring as little as 1 µL of sample

> Ready-to-use kits are fully qualified for reliable use in clinical research

> Accuracy and precision meets or exceeds ELISA performance


Gyros AB today announced that EMD Millipore, Life Science division of Merck KGaA of Darmstadt, Germany, has released five new immunoassay kits designed specifically for use on Gyrolab™xP workstation. The new, fully qualified GyroMark™ HT kits from EMD Millipore will enable clinical researchers and drug developers to generate valuable research data much faster than typical ELISA kits.

Traditional ELISAs can consume significant time, sample and reagents. With the fully automated, walk-away system from Gyros, up to 480 data points can be generated in a run.

"We are very pleased to be able to partner with Gyros to fill a commercial need to provide immunoassay kits requiring only nanoliter sample volume on a truly high-throughput platform," says Jehangir Mistry, PhD, General Manager, Multiplex & Immunoassays at EMD Millipore.

The initial launch includes five assays for important metabolic and toxicity biomarkers, such as GLP-1, Insulin, Clusterin and KIM-1. EMD Millipore plans to release additional kits this year and is offering custom kits for companies who have specific needs or unique or novel antibodies.

Because the Gyrolab platform employs microfluidic technology with parallel processing, it offers many advantages over traditional assays in addition to reagent and time savings. GyroMark HT assays provide:

> accuracy over a four-log dynamic range (compared to two logs for ELISAs,
> elimination of cross-talk and plate position artifacts
> simplified sample prep (only 1:2 dilution necessary) with reduced matrix interference

Gyros' Global Marketing Director Maria Hjortsmark commented: "Gyrolab system revolutionizes immunoassays, enabling scientists to analyze large numbers of samples in parallel, at nanoliter scale and using a fully automated system. We are delighted that EMD Millipore has now chosen to work with us to develop off-the-shelf kits, to further reduce time to results, freeing up analyst time and offering an easier route to robust, reproducible data."

For more information on these new kits, please contact Cindy Fry, BS, MBA, EMD Millipore, +1 636-720-1078, cindy.fry@emdmillipore.com.


Media Contact:

Leslie Eisenberg, Feinstein Kean Healthcare, 617-244-3872, leslie.eisenberg@fkhealth.com

Note:EMD Millipore is known as Merck Millipore outside of the U.S. and Canada.


Enquiries:

For Gyros AB
Katie Odgaard / Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947 / +44 (0) 7811 996 942
Skype: kodgaard / lorna.cuddon
Email: katie.odgaard@zymecommunications.com / lorna.cuddon@zymecommunications.com
www.zymecommunications.com


Notes to editors:

About Gyros (www.gyros.com)

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The Gyros™ immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.

Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nano-liter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.

The company is based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors.

   
Record changed: 2017-04-02

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px

More documents for Gyros (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Partnering 600x60px




» top